The implementation of the Oncology Care Model has brought profound culture changes to how oncologists take care of patients and how they operate practices, explained Lucio Gordan, MD, of Florida Cancer Specialists.
The implementation of the Oncology Care Model has brought profound culture changes to how oncologists take care of practices and how they operate practices, explained Lucio Gordan, MD, of Florida Cancer Specialists.
Transcript (slightly modified)
How do practices and payers work together to implement OCM?
OCM has brought a very profound change to oncology practice in the country. One hundred ninety practices are participating in OCM these days, and we have to go through culture changes as to how we take care of patients, operational changes, revenue cycle changes, communication changes as to how the operating team communicates with the providers, the physicians, nurse practitioners, etc. It has certainly been a very profound, interesting, rewarding, and with many challenges ahead still, experience for all of us at Florida Cancer Specialists. So, how we did it. Obviously, there was a process of educating the staff, educating the physicians. We are a large practice in Florida. We have about 100+ offices, almost 400 providers, so we had to do webinars to discuss oncology care model, we got physicians involved via e-mail, Q&A, all those things to make it happen. So, it was a very laborious process that continues to be active and we perfect every time.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Mirvetuximab Soravtansine-gynx Granted Full FDA Approval for FRα+ Platinum-Resistant Ovarian Cancer
March 22nd 2024Mirvetuximab soravtansine-gynx (Elahere) received full FDA approval for the treatment of folate receptor alpha–positive (FRα+), platinum-resistant ovarian cancer (PROC) based on findings from the confirmatory phase 3 MIRASOL trial.
Read More
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More